Risk of termination of alliances involving joint development, sales and similar activities
First written in FY2016. 4 of 10 entries say "Restated". Latest entry: FY2026.
Mochida Pharmaceutical moved to the "Worse" side of this theme in 2023, the same year as the typical company in this theme.
The whole theme swung hardest in 2023: 4 of 18 companies on the "Worse" side.
2 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「The Group has business alliances with other companies in each division, including joint research, development and sales and the licensing in and out of products. These alliances could be terminated in the future for any number of reasons. In addition, if expected benefits from investments in or acquisitions of companies are not fully realized due to poor sales, shipment suspensions or other factors, the Group could generate less revenue than initially forecast or expected due to the loss of anticipated future sales and business opportunities.」
In addition to the existing risk of alliance termination, the scope now includes the risk that expected benefits from investments and acquisitions will not be realized. - FY2025MaterialisedAnnual report
「The material contracts that ended during the current consolidated fiscal year are as follows: Idorsia Pharmaceuticals Joint development, import and joint sales of the insomnia treatment Quviviq tablets. Shionogi & Co.,Ltd. Supply and exclusive sales of the insomnia treatment Quviviq tablets.」
The disclosure states that the material contracts with Idorsia Pharmaceuticals and Shionogi & Co.,Ltd. for the joint development and sales, among other activities, of Quviviq tablets have ended. - FY2024-Q1MaterialisedAnnual report
「Pfizer Inc. Japan Joint development, importation and joint sales of the antidepressant “MD-120” 2019」
The disclosure lists the joint development, import and joint sales agreement for MD-120 with Pfizer株式会社 as a material contract that ended during the first quarter of the current consolidated fiscal year. An event involving the termination of an alliance agreement has occurred. - FY2023-Q3MaterialisedAnnual report
「Fuji Pharma Co.,Ltd. Japan Joint development, procurement and sales of the biosimilar "Filgrastim BS Mochida" 2010 Janssen Pharma Co., Ltd. Japan Procurement and exclusive sales of the antineoplastic agent "Doxil" 2017」
The material contracts that ended during the third quarter of the current consolidated fiscal year include the joint development, procurement and sales agreement for Filgrastim BS Mochida and the procurement and exclusive sales agreement for Doxil. - FY2022RestatedAnnual report
「The Group has business alliances with other companies in each division, including joint research, development and sales and the licensing in and out of products. These alliances could be terminated in the future for any number of reasons, in which case the Group could generate less revenue than initially forecast or expected due to the loss of anticipated future sales and business opportunities.」
The risk of losing anticipated future sales and business opportunities due to termination of alliances for joint research, development and sales and the licensing in and out of products has been reconfirmed. - FY2021RestatedAnnual report
「The Group has business alliances with other companies in each division, including joint research, development and sales and the licensing in and out of products. These alliances could be terminated in the future for any number of reasons, in which case the Group could generate less revenue than initially forecast or expected due to the loss of anticipated future sales and business opportunities.」
The risk of losing anticipated future sales and business opportunities due to termination of alliances for joint research, development and sales and the licensing in and out of products has been reconfirmed. - FY2020MitigatedAnnual report
「To avoid risks arising from changes in the business environment, the Group recorded a contract loss of ¥3,000 million as an extraordinary loss for the current period resulting from changes to the terms of alliance agreements relating to the sale of certain prescription drugs.」
The disclosure states that risks arising from changes in the business environment were avoided by changing the terms of the alliance agreements, while a contract loss of ¥3,000 million was recorded. - FY2019RestatedAnnual report
「However, these alliances could be terminated in the future for any number of reasons.」
The risk of termination of business alliances for joint development and sales, product introduction and other activities is reiterated. - FY2018RestatedAnnual report
「However, these alliances could be terminated in the future for any number of reasons.」
The risk of termination of business alliances for joint development and sales, among other activities, is reiterated. - FY2016First statedAnnual report
「These alliances could be terminated in the future for any number of reasons.」
Risks relating to business alliances for joint development and sales, product introduction and other activities.